People News: Sunovion Pharmaceuticals, ImpactRx

Sunovion Pharmaceuticals has announced that Mark Iwicki, formerly president and chief operating officer at Sunovion, has been appointed as the company's president and CEO. Iwicki was hired by Sepracor – Sunovion's predecessor until the company changed names in 2010 – as EVP and chief commercial officer in 2007. With more than 20 years experience in the industry, Iwicki's leadership roles have included positions with Novartis, Merck and Astra Merck Inc., and he currently serves as a board member of The Pharmaceutical Research and Manufacturers of America (PhRMA).

ImpactRx, a company dedicated to tracking, evaluating and reporting on the effects of promotional pharma activities on physician prescribing behavior, has announced the appointment of Gregory Ellis to the position of president and CEO. Ellis joins ImpactRx from Rosetta, where he was previously a senior partner at the firm since 2002 and helped the agency grow from $5 million to $240 million in annual revenue over a nine year period. With more than 30 years experience in the information, analysis and consulting market, Ellis formed his career at such market research firms as IRI, Nielsen and Opinion Research Corporation.

You must be a registered member of MMM to post a comment.
close

Next Article in Careers

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.